Spring 2019
RiverVest closes on its oversubscribed $184.4 million RiverVest Fund IV
The fund marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Dec. 31 to $832 million.

Net IRRs of RiverVest Funds II and II are in the top 5% of all U.S. venture funds for their vintage years, as of Dec. 31, based on most-recent Cambridge Associates data.*

*As compared to the Cambridge Associates 2008 and 2014, respectively, U.S. HealthCare VC and All U.S. VC universes as of September 30, 2018; data were provided at no charge.
RiverVest is recognized as Investor of the Year by the St. Louis Business Journal.

 RiverVest ranks among the best venture funds in the nation based on money returned to investors.
Sivan Weitzman joins RiverVest as its first CFO.

Weitzman brings her experience as CFO at an Israeli investment firm where, during her 13 years there, assets under management grew from $250 million to $14 billion.
Nancy Hong recently attended “Accelerating Precision Medicine through Investment” at Harvard Business School that brought together leading VCs, disease foundations, academic leaders from HBS, Harvard University, MIT, Dana Farber, and financial institutions such as UBS, Goldman Sachs, Bank of America Merrill Lynch. Discussion focused on best practices and novel models in the area of impact investing and venture philanthropy.
Portfolio companies in the news
Allakos presented data that demonstrates its drug's effectiveness treating eosinophil and mast cell-related diseases at the company's investor day.

Arch Oncology raised Series B financing and also announced first patient dosed in clinical trial of its antibody therapy.

Cardialen closed $17M Series B financing.

Mirum Pharmaceuticals secured $120M Series A financing and also presented data showing the positive impact of its drugs on patients with cholestatic liver diseases a t the 2019 International Liver Congress.

Spruce Biosciences presented positive topline data.

WUGEN announced e xclusive license agreement for CAR-T therapy from Wash U.
People in the news
VentureMed Group names J. Robert Paulson Jr., CEO

VentureMed Group, Inc. announced that J. Robert Paulson, Jr. has been appointed president and chief executive officer, and a member of the Company's board of directors.

Standard Bariatrics names Kurt Azarbarzin as Chairman

Standard Bariatrics, Inc. announced the appointment of Kurt Azarbarzin as chairman of the board of directors.

RiverVest Venture Partners®  is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.